Huaren Pharmaceutical’s wholly-owned subsidiary obtains registration certificate for phenylephrine hydrochloride injection
June 11, 2025
Source: drugdu
50
On June 9, Huaren Pharmaceutical announced that its wholly-owned subsidiary Anhui Hengxing Pharmaceutical has obtained the Drug Registration Certificate for Phenylephrine Hydrochloride Injection approved and issued by the State Drug Administration. The drug is a prescription drug with a specification of 5ml: 0.5mg. It is registered as a Class 3 chemical drug. The drug approval number is National Medicine Standard H20254431, which is valid until June 2, 2030.
Phenylephrine hydrochloride injection is mainly used to treat clinical hypotension caused by vasodilation during anesthesia and is listed as a Class B product of the national medical insurance. According to statistics from Yaozhi.com, the sales of this drug in domestic hospitals in 2024 will be 119 million yuan.
In the first quarter of 2025, Huaren Pharmaceutical achieved revenue of 303 million yuan and net profit attributable to shareholders of the parent company of 16.03 million yuan.
https://finance.eastmoney.com/a/202506093425445718.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Bedaquiline Fumarate API Approved for Marketing, Enriching Anti-TB Drug Product Line July 25, 2025
- Huadong Medicine’s subsidiary’s Caspofungin Acetate for Injection approved by the U.S. FDA July 25, 2025
- Good news from AstraZeneca July 25, 2025
- A breakthrough in the cure of hepatitis B is in sight, and the share prices of leading pharmaceutical companies have doubled July 25, 2025
- A new hotspot in the innovative drug market July 25, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
